PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS Jan 12, 2022
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program Jan 12, 2022
Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure… Jan 11, 2022
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder to Include Additional Behavioral… Jan 5, 2022